Last $10.96 USD
Change Today -0.20 / -1.79%
Volume 505.2K
BCRX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:34 AM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

biocryst pharmaceuticals inc (BCRX) Snapshot

Open
$11.47
Previous Close
$11.16
Day High
$11.48
Day Low
$10.68
52 Week High
08/11/14 - $14.62
52 Week Low
12/23/13 - $6.88
Market Cap
787.6M
Average Volume 10 Days
1.0M
EPS TTM
$-0.64
Shares Outstanding
71.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOCRYST PHARMACEUTICALS INC (BCRX)

biocryst pharmaceuticals inc (BCRX) Related Businessweek News

No Related Businessweek News Found

biocryst pharmaceuticals inc (BCRX) Details

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop drugs through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as to treat acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company’s product candidates also comprise BCX4161, a Phase II oral serine protease inhibitor for hereditary angioedema (HAE); and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses, including hemorrhagic fever viruses. Its pre-clinical products also include Two 2nd generation HAE compounds for the prevention of HAE attacks. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

40 Employees
Last Reported Date: 03/10/14
Founded in 1986

biocryst pharmaceuticals inc (BCRX) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $475.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $387.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $418.9K
Senior Vice President of Drug Discovery
Total Annual Compensation: $341.5K
Vice President, General Counsel and Corporate...
Total Annual Compensation: $231.7K
Compensation as of Fiscal Year 2013.

biocryst pharmaceuticals inc (BCRX) Key Developments

BioCryst Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 08:30 AM

BioCryst Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 08:30 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

BioCryst Pharmaceuticals, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 09:45 AM

BioCryst Pharmaceuticals, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 09:45 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Jon P. Stonehouse, Chief Executive Officer, President and Executive Director.

Biocryst Pharmaceuticals, Inc. Announces Un-Audited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revised Cash Flow Guidance for the Year 2014; Provides Update on Activities to Initiate the (Oral ProphylaxiS-2) OPuS-2 Clinical Trial

BioCryst Pharmaceuticals, Inc. announced un-audited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company’s revenues increased to $3.2 million from $2.4 million in the third quarter of 2013. This increase was partially offset by the lack of RAPIVAB(TM) (peramivir injection) collaborative revenue in the third quarter. The net loss was $8.7 million, or $0.12 per basic and diluted share, as compared to a net loss of $8.0 million, or $0.14 per basic and diluted share, for the third quarter of 2013. Loss from operations was $11.6 million compared to $6.9 million in last year. For the nine months, the company’s revenues increased to $8.2 million from $6.8 million in the same period of 2013. The increase in 2014 was primarily due to increased collaboration revenue associated with the BCX4430 NIAID development contract, and partially offset by lower collaborative revenue associated with a reduction in reimbursable RAPIVAB development expenses. The net loss increased to $33.5 million, or $0.52 per basic and diluted share, compared to a net loss of $24.7 million, or $0.46 per basic and diluted share for the same period last year. Loss from operations was $30.6 million compared to $24.4 million in last year. The company expected its 2014 net operating cash use to be in the lower end of previously disclosed range of $35 to $43 million. The company announced activities are underway to initiate the (Oral ProphylaxiS-2) OPuS-2 clinical trial of BCX4161 before the end of 2014. OPuS-2 is a 12-week, three-arm, parallel cohort design trial to evaluate the efficacy and safety of two different dose regimens of BCX4161 administered three-times daily, 300 mg and 500 mg, compared with placebo. The trial, to be conducted in the U.S. and selected European countries, is expected to enroll approximately 100 HAE patients whose average historical attack rate is lower than that observed for patients enrolled in OPuS-1. The primary efficacy endpoint for the trial will be the mean angioedema attack rate for each BCX4161 dose group compared to placebo. The OPuS-2 trial will use 100 mg soft-gel capsules that have demonstrated relative bioavailability of approximately 80% compared with the hard gel capsule formulation used in OPuS-1, which tested 400mg three-times daily. Non-clinical safety studies for two second generation compounds for the treatment of HAE are progressing as planned, and first-in-human clinical trials are expected to begin during the second quarter of 2015. Non-human primate (NHP) studies with BCX4430 have commenced to evaluate whether BCX4430 shows a meaningful benefit for survival in Ebola virus NHP disease models. A dose-ranging study of BCX4430 for the treatment of cynomolgus macaques infected with Ebola virus demonstrated a statistically significant prolongation of survival at the high dose regimen tested; however, no animals survived past 21 days. An additional NIAID-funded study to evaluate BCX4430 in Rhesus macaques infected with Ebola virus will include a higher dose regimen of BCX4430, and is expected to start in November. In addition, BioCryst anticipates filing a BCX4430 Investigational New Drug (IND) application with the Food and Drug Administration (FDA) in November.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCRX:US $10.96 USD -0.20

BCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Daiichi Sankyo Co Ltd ¥1,687 JPY -3.00
Dyax Corp $15.30 USD -0.01
Gilead Sciences Inc $95.07 USD -13.38
Pharming Group NV €0.34 EUR -0.003
Shire PLC 4,637 GBp +8.00
View Industry Companies
 

Industry Analysis

BCRX

Industry Average

Valuation BCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 42.8x
Price/Book 9.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 34.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCRYST PHARMACEUTICALS INC, please visit www.biocryst.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.